+86-27-65522453 sales@sun-shinechem.com

Vesatolimod(GS-9620)

Catalog No.: 19529
Cas No.: 1228585-88-3
Purity : 98% Min.
19529 - Vesatolimod(GS-9620) | CAS 1228585-88-3

Catalog number : 19529

CAS number : 1228585-88-3

Molecular Formula : C22H30N6O2

Molecular Weight : 410.51

Iupac Chemical Name : 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one

Smile : O=C1NC2=C(N)N=C(OCCCC)N=C2N(CC3=CC=CC(CN4CCCC4)=C3)C1

InChiKey : VFOKSTCIRGDTBR-UHFFFAOYSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsGS-9620; GS 9620; GS9620; Vesatolimod
Molecular FormulaC22H30N6O2
Molecular Weight410.51
Appearanceoff-white solid to light yellow solid
Purity98% Min.
SolubilitySoluble in DMSO, not in water
Storage3 years -20ºCpowder 
Shipping ConditionShipped under ambient temperature 
SmileO=C1NC2=C(N)N=C(OCCCC)N=C2N(CC3=CC=CC(CN4CCCC4)=C3)C1
InChiKeyVFOKSTCIRGDTBR-UHFFFAOYSA-N
InChiInChI=1S/C22H30N6O2/c1-2-3-11-30-22-25-20(23)19-21(26-22)28(15-18(29)24-19)14-17-8-6-7-16(12-17)13-27-9-4-5-10-27/h6-8,12H,2-5,9-11,13-15H2,1H3,(H,24,29)(H2,23,25,26)
DescriptionGS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7.
Targets
TLR7 
In vitro

GS-9620 potently inhibited viral replication in peripheral blood mononuclear cells(PBMCs), particularly when added 24 to 48 hours prior to HIV infection (EC50= 27 nM). Depletion of pDCs, but not other immune cell subsets from PBMC cultures, suppressed GS-9620 antiviral activity.

In vivoShort-term oral administration of GS-9620 provides long-term suppression of serum and liver HBV DNA. GS-9620 administration induces production of IFN-α and other cytokines and chemokines, and activates ISGs, natural killer cells, and lymphocyte subsets. Its treatment reduces viral DNA, Serum levels of HB surface antigen, HB e antigen and numbers of HBV antigen-positive hepatocytes while hepatocyte apoptosis increases. Currently, GS-9620 is under clinical evaluation for treating chronic HBV infection and for reducing latent reservoirs in virally-suppressed HIV-infected patients.


1228585-88-3 - Request Bulk Quote

×
1228585-88-3 - Request Bulk Quote
Change